Voyager Therapeutics (VYGR) Stock Forecast, Price Target & Predictions
VYGR Stock Forecast
Voyager Therapeutics stock forecast is as follows: an average price target of $18.00 (represents a 213.04% upside from VYGR’s last price of $5.75) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
VYGR Price Target
The average price target for Voyager Therapeutics (VYGR) is $18.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $18.00 to $18.00. This represents a potential 213.04% upside from VYGR's last price of $5.75.
VYGR Analyst Ratings
According to 4 Wall Street analysts, Voyager Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for VYGR stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Voyager Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 13, 2024 | Jay Olson | Oppenheimer | $18.00 | $6.92 | 160.12% | 213.04% |
| Sep 25, 2024 | Jack Allen | Robert W. Baird | $18.00 | $6.04 | 198.01% | 213.04% |
| May 14, 2024 | Laura Chico | Wedbush | $8.00 | $8.48 | -5.66% | 39.13% |
| Jan 02, 2024 | Jim Birchenough | Wells Fargo | $14.00 | $9.00 | 55.56% | 143.48% |
| May 10, 2023 | Joon Lee | Truist Financial | $18.00 | $9.88 | 82.19% | 213.04% |
The latest Voyager Therapeutics stock forecast, released on Nov 13, 2024 by Jay Olson from Oppenheimer, set a price target of $18.00, which represents a 160.12% increase from the stock price at the time of the forecast ($6.92), and a 213.04% increase from VYGR last price ($5.75).
Voyager Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 4 |
| Avg Price Target | - | $18.00 | $14.50 |
| Last Closing Price | $5.75 | $5.75 | $5.75 |
| Upside/Downside | -100.00% | 213.04% | 152.17% |
In the current month, the average price target of Voyager Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Voyager Therapeutics's last price of $5.75. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 02, 2024 | Citigroup | Buy | Initialise | |
| Nov 13, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Oct 16, 2024 | Wedbush | Buy | Buy | Hold |
| Jul 31, 2024 | Wedbush | Buy | Buy | Hold |
| May 14, 2024 | Wedbush | Neutral | Neutral | Hold |
| May 10, 2023 | UBS | Buy | Initialise |
Voyager Therapeutics's last stock rating was published by Citigroup on Dec 02, 2024. The company Initialise its VYGR rating from "null" to "Buy".
Voyager Therapeutics Financial Forecast
Voyager Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $4.85M | $150.48M | $-41.09M | $41.09M | $712.00K | $658.00K | $28.07M | $1.48M | $1.36M | $6.50M | $6.54M | $117.84M | $28.68M | $18.07M | $32.67M | $20.43M |
| Avg Forecast | $39.80M | $37.74M | $35.78M | $33.92M | $10.43M | $17.17M | $17.63M | $11.69M | $17.18M | $11.70M | $9.51M | $9.48M | $20.63M | $2.91M | $1.60M | $10.04M | $3.73M | $9.42M | $7.03M | $12.71M | $4.30M | $2.14M | $4.18M | $7.55M | $16.59M | $15.05M | $16.52M | $13.55M | $9.93M | $6.88M |
| High Forecast | $66.42M | $62.97M | $59.70M | $56.60M | $17.41M | $28.65M | $29.42M | $19.04M | $21.34M | $12.20M | $9.51M | $15.82M | $23.05M | $2.91M | $2.67M | $16.75M | $6.23M | $9.42M | $7.03M | $12.71M | $4.30M | $2.14M | $4.18M | $7.55M | $16.59M | $15.05M | $16.52M | $13.55M | $9.93M | $6.88M |
| Low Forecast | $6.41M | $6.08M | $5.76M | $5.47M | $1.68M | $2.77M | $2.84M | $801.85K | $13.10M | $11.21M | $9.51M | $1.53M | $19.22M | $2.91M | $258.08K | $1.62M | $601.27K | $9.42M | $7.03M | $12.71M | $4.30M | $2.14M | $4.18M | $7.55M | $16.59M | $15.05M | $16.52M | $13.55M | $9.93M | $6.88M |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 8 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 9 | 9 | 9 | 9 | 5 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.03% | 14.99% | -11.01% | 4.36% | 0.10% | 0.05% | 6.53% | 0.69% | 0.33% | 0.86% | 0.39% | 7.83% | 1.74% | 1.33% | 3.29% | 2.97% |
Voyager Therapeutics's average Quarter revenue forecast for Sep 23 based on 4 analysts is $2.91M, with a low forecast of $2.91M, and a high forecast of $2.91M. VYGR's average Quarter revenue forecast represents a -40.09% decrease compared to the company's last Quarter revenue of $4.85M (Jun 23).
Voyager Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 8 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 9 | 9 | 9 | 9 | 5 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-25.43M | $122.88M | $-24.56M | $15.78M | $-18.16M | $-18.54M | $7.19M | $-23.91M | $-28.93M | $-20.38M | $-14.94M | $86.67M | $-7.75M | $-23.42M | $-11.82M | $-14.29M |
| Avg Forecast | $-14.17M | $-13.44M | $-12.74M | $-12.08M | $-3.72M | $-6.11M | $-6.28M | $-4.16M | $-6.12M | $-4.17M | $-3.39M | $4.46M | $-7.35M | $-1.04M | $-570.35K | $4.77M | $-17.21M | $-3.40M | $-2.54M | $5.10M | $-1.55M | $-774.39K | $-1.51M | $-22.84M | $-5.99M | $-5.44M | $-5.97M | $-27.28M | $-3.59M | $-2.48M |
| High Forecast | $-2.28M | $-2.17M | $-2.05M | $-1.95M | $-598.63K | $-984.98K | $-1.01M | $-285.53K | $-4.66M | $-3.99M | $-3.39M | $5.35M | $-6.84M | $-1.04M | $-91.90K | $5.72M | $-13.77M | $-3.40M | $-2.54M | $6.12M | $-1.55M | $-774.39K | $-1.51M | $-18.28M | $-5.99M | $-5.44M | $-5.97M | $-21.82M | $-3.59M | $-2.48M |
| Low Forecast | $-23.65M | $-22.42M | $-21.26M | $-20.16M | $-6.20M | $-10.20M | $-10.48M | $-6.78M | $-7.60M | $-4.34M | $-3.39M | $3.57M | $-8.21M | $-1.04M | $-951.80K | $3.81M | $-20.65M | $-3.40M | $-2.54M | $4.08M | $-1.55M | $-774.39K | $-1.51M | $-27.41M | $-5.99M | $-5.44M | $-5.97M | $-32.73M | $-3.59M | $-2.48M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 44.58% | 25.77% | 1.43% | -4.64% | 7.15% | -3.64% | -4.63% | 30.88% | 19.18% | 0.89% | 2.49% | -15.93% | 1.30% | 0.86% | 3.29% | 5.75% |
4 analysts predict VYGR's average Quarter EBITDA for Jun 23 to be $-570.35K, with a high of $-91.90K and a low of $-951.80K. This is -100.46% lower than Voyager Therapeutics's previous annual EBITDA (Mar 23) of $122.88M.
Voyager Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 8 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 9 | 9 | 9 | 9 | 5 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-22.21M | $124.04M | $-23.63M | $17.62M | $-18.87M | $-21.29M | $5.71M | $-25.14M | $-30.12M | $-21.65M | $-15.93M | $85.61M | $-8.68M | $-24.26M | $-12.57M | $-15.01M |
| Avg Forecast | $-33.67M | $-33.68M | $-31.72M | $-31.73M | $-30.08M | $-24.09M | $-22.43M | $-27.66M | $-20.79M | $-25.73M | $-23.67M | $-33.55M | $-16.72M | $-33.62M | $-32.90M | $-35.88M | $-18.35M | $-18.31M | $-27.54M | $-38.37M | $-36.01M | $-43.15M | $-42.02M | $-24.27M | $-32.32M | $-10.87M | $-41.35M | $-28.26M | $-41.80M | $-41.94M |
| High Forecast | $3.05M | $3.05M | $2.87M | $2.87M | $2.72M | $2.18M | $2.03M | $-17.37M | $-7.72M | $2.33M | $2.14M | $-26.84M | $-14.45M | $3.04M | $2.98M | $-28.70M | $-14.68M | $-18.31M | $-27.54M | $-30.70M | $-36.01M | $-43.15M | $-42.02M | $-19.42M | $-32.32M | $-10.87M | $-41.35M | $-22.60M | $-41.80M | $-41.94M |
| Low Forecast | $-62.94M | $-62.95M | $-59.30M | $-59.32M | $-56.24M | $-45.04M | $-41.93M | $-46.32M | $-30.89M | $-48.10M | $-44.25M | $-40.26M | $-17.57M | $-62.84M | $-61.51M | $-43.06M | $-22.02M | $-18.31M | $-27.54M | $-46.05M | $-36.01M | $-43.15M | $-42.02M | $-29.13M | $-32.32M | $-10.87M | $-41.35M | $-33.91M | $-41.80M | $-41.94M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.67% | -3.46% | 1.29% | -0.96% | 0.69% | 0.55% | -0.16% | 0.58% | 0.72% | 0.89% | 0.49% | -7.88% | 0.21% | 0.86% | 0.30% | 0.36% |
Voyager Therapeutics's average Quarter net income forecast for Jun 23 is $-32.90M, with a range of $-61.51M to $2.98M. VYGR's average Quarter net income forecast represents a -126.53% decrease compared to the company's last Quarter net income of $124.04M (Mar 23).
Voyager Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 8 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 9 | 9 | 9 | 9 | 5 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $8.29M | $9.03M | $8.46M | $7.31M | $7.55M | $7.66M | $8.35M | $8.71M | $10.44M | $9.74M | $8.27M | $8.28M | $8.24M | $10.21M | $9.89M | $8.46M |
| Avg Forecast | $19.49M | $18.48M | $17.52M | $16.61M | $5.11M | $8.41M | $8.63M | $5.73M | $8.41M | $5.73M | $4.66M | $4.64M | $10.10M | $1.42M | $784.40K | $4.92M | $1.83M | $4.61M | $3.44M | $6.23M | $2.10M | $1.05M | $2.04M | $3.70M | $8.12M | $7.37M | $8.09M | $11.89M | $4.86M | $3.37M |
| High Forecast | $32.53M | $30.84M | $29.24M | $27.72M | $8.53M | $14.03M | $14.41M | $9.33M | $10.45M | $5.97M | $4.66M | $7.75M | $11.29M | $1.42M | $1.31M | $8.21M | $3.05M | $4.61M | $3.44M | $6.23M | $2.10M | $1.05M | $2.04M | $3.70M | $8.12M | $7.37M | $8.09M | $14.26M | $4.86M | $3.37M |
| Low Forecast | $3.14M | $2.98M | $2.82M | $2.68M | $823.30K | $1.35M | $1.39M | $392.69K | $6.42M | $5.49M | $4.66M | $748.04K | $9.41M | $1.42M | $126.39K | $792.23K | $294.46K | $4.61M | $3.44M | $6.23M | $2.10M | $1.05M | $2.04M | $3.70M | $8.12M | $7.37M | $8.09M | $9.51M | $4.86M | $3.37M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.57% | 1.84% | 4.63% | 1.58% | 2.19% | 1.23% | 3.97% | 8.30% | 5.10% | 2.64% | 1.02% | 1.12% | 1.02% | 0.86% | 2.03% | 2.51% |
Voyager Therapeutics's average Quarter SG&A projection for Sep 23 is $1.42M, based on 4 Wall Street analysts, with a range of $1.42M to $1.42M. The forecast indicates a -82.83% fall compared to VYGR last annual SG&A of $8.29M (Jun 23).
Voyager Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 8 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 9 | 9 | 9 | 9 | 5 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.51 | $3.05 | $-0.61 | $0.46 | $-0.49 | $-0.56 | $0.15 | $-0.67 | $-0.80 | $-0.58 | $-0.43 | $2.30 | $-0.23 | $-0.66 | $-0.35 | $-0.41 |
| Avg Forecast | $-0.58 | $-0.58 | $-0.55 | $-0.55 | $-0.52 | $-0.42 | $-0.39 | $-0.48 | $-0.36 | $-0.44 | $-0.41 | $-0.44 | $-0.29 | $-0.58 | $-0.57 | $-0.33 | $-0.55 | $-0.32 | $-0.48 | $-0.37 | $-0.62 | $-0.75 | $-0.73 | $-0.64 | $-0.56 | $-0.19 | $-0.72 | $-0.79 | $-0.72 | $-0.73 |
| High Forecast | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 | $0.04 | $0.04 | $-0.30 | $-0.13 | $0.04 | $0.04 | $0.04 | $-0.25 | $0.05 | $0.05 | $0.03 | $0.05 | $-0.32 | $-0.48 | $-0.37 | $-0.62 | $-0.75 | $-0.73 | $-0.64 | $-0.56 | $-0.19 | $-0.72 | $-0.79 | $-0.72 | $-0.73 |
| Low Forecast | $-1.09 | $-1.09 | $-1.03 | $-1.03 | $-0.97 | $-0.78 | $-0.72 | $-0.80 | $-0.53 | $-0.83 | $-0.76 | $-0.82 | $-0.30 | $-1.09 | $-1.06 | $-0.61 | $-1.02 | $-0.32 | $-0.48 | $-0.37 | $-0.62 | $-0.75 | $-0.73 | $-0.64 | $-0.56 | $-0.19 | $-0.72 | $-0.79 | $-0.72 | $-0.73 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.90% | -9.38% | 1.12% | -1.45% | 1.03% | 1.51% | -0.24% | 0.90% | 1.10% | 0.90% | 0.77% | -12.21% | 0.32% | 0.84% | 0.48% | 0.56% |
According to 4 Wall Street analysts, Voyager Therapeutics's projected average Quarter EPS for Jun 23 is $-0.57, with a low estimate of $-1.06 and a high estimate of $0.05. This represents a -118.65% decrease compared to VYGR previous annual EPS of $3.05 (Mar 23).
Voyager Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| INZY | Inozyme Pharma | $2.94 | $16.00 | 444.22% | Buy |
| XFOR | X4 Pharmaceuticals | $0.74 | $3.67 | 395.95% | Buy |
| PDSB | PDS Bio | $1.96 | $9.00 | 359.18% | Buy |
| ABOS | Acumen Pharmaceuticals | $1.96 | $7.00 | 257.14% | Buy |
| VYGR | Voyager Therapeutics | $6.25 | $18.00 | 188.00% | Buy |
| ANNX | Annexon | $4.88 | $14.00 | 186.89% | Buy |
| TERN | Terns Pharmaceuticals | $6.80 | $18.67 | 174.56% | Buy |
| MREO | Mereo BioPharma Group | $3.40 | $8.00 | 135.29% | Buy |
| DAWN | Day One Biopharmaceuticals | $12.64 | $24.00 | 89.87% | Buy |
| LPTX | Leap Therapeutics | $3.11 | $5.50 | 76.85% | Buy |
| HOOK | HOOKIPA Pharma | $2.13 | $3.00 | 40.85% | Buy |
| ARWR | Arrowhead Pharmaceuticals | $22.27 | $27.74 | 24.56% | Buy |
| PRQR | ProQR Therapeutics | $2.94 | $3.63 | 23.47% | Buy |